EMA backs Novartis' Afinitor for breast cancer; Max Planck finishes Florida center; Perrigo to invest in R&D;

 @FierceBiotech: Check out the Fierce team's BIO 2012 convention slideshow featuring the faces of biotech leaders. More | Follow @FierceBiotech

 @JohnCFierce: Benefits of scientific understanding exceed fears of Crichton-style weaponized bird flu fears. More | Follow @JohnCFierce

> The EMA is recommending approval of Novartis' ($NVS) Afinitor for advanced breast cancer, improving the Big Pharma's chances of making the drug into a blockbuster performer.  Story

> Employees are moving into the $64 million Max Planck Florida Institute in Jupiter. Story

> Perrigo says it will invest $40 million in Israel to expand its R&D and manufacturing operations. Perrigo will also add 100 new workers to its fast-growing Israeli operation. Report

Pharma News

 @FiercePharma: Is Madagascar 3's friendly lion a dangerous drug spokesman? Groups ask FTC to investigate Merck's Claritin campaign. More | Follow @FiercePharma

> Roche overlooks 80,000 adverse reaction complaints. Story

> FDA delivers Xarelto bad news to J&J, Bayer. News

> Abbott stands alone in challenge to biosimilars law. Article

Medical Device News

 @FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey  | Follow @FierceMedDev

> Olympus confirms fundraising negotiations in accounting scandal's wake. More

> DBS for Parkinson's patients still going strong after three years. Story

> Medtronic's stent graft picked for FDA pilot program. Article

And Finally… Investigators have developed a new mouse model for supertasting  - the ability to strong detect flood flavors, which can influence food choice and health status. The mice have taste buds which overexpress brain-derived neurotrophic factor. Release

 

Suggested Articles

Werewolf is launching with $56 million and an approach that can cut through the toxic effects that have limited certain cancer-killing agents.

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.